TEBENTAFUSP

602 reported adverse events

Drug classes: Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC]

These side effects are most commonly reported by patients taking TEBENTAFUSP:

# Side effect Count
0 CYTOKINE RELEASE SYNDROME 118
1 PYREXIA 107
2 DISEASE PROGRESSION 73
3 HYPOTENSION 70
4 RASH 69
5 MALIGNANT NEOPLASM PROGRESSION 61
6 CHILLS 59
7 PRODUCT DOSE OMISSION ISSUE 56
8 PRURITUS 44
9 NAUSEA 40
See all common reactions for TEBENTAFUSP

TEBENTAFUSP is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 MAGNETIC RESONANCE IMAGING HEPATOBILIARY ABNORMAL 1 0.1250
1 HEPATOBILIARY NEOPLASM 1 0.1000
2 UVEAL MELANOMA 5 0.0893
3 ANTERIOR SEGMENT NEOVASCULARISATION 1 0.0833
4 EXERTIONAL RHABDOMYOLYSIS 3 0.0811
5 METASTATIC OCULAR MELANOMA 2 0.0800
6 T-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA 1 0.0500
7 DELAYED ISCHAEMIC NEUROLOGICAL DEFICIT 1 0.0476
8 RESPIRATORY TRACT NEOPLASM 1 0.0417
9 CHOROIDAL DYSTROPHY 1 0.0208
See all enriched reactions for TEBENTAFUSP